Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH -2.08%66 3-Year EBITDA Growth Rate is 9.60% as of Jun. 2026. GuruFocus rates SOPH with a GF Score™ of 66/100 and a GF Value™ of $5.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 50.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sophia Genetics was 15.00% per year. The lowest was -25.70% per year. And the median was -0.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sophia Genetics 3-Year EBITDA Growth Rate Related Terms
SOPH vs CTEV, PHR, WEAV: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Sophia Genetics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.60% mean?
Sophia Genetics (SOPH) has a 3-Year EBITDA Growth Rate of 9.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #265 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 50.5%.
Is Sophia Genetics' 3-Year EBITDA Growth Rate too high?
Sophia Genetics' current 3-Year EBITDA Growth Rate is 9.60%. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Sophia Genetics' value of 9.60% is 3% below this industry median. Based on the distribution chart, Sophia Genetics ranks #265 out of 525 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' 3-Year EBITDA Growth Rate compare to CTEV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #265 out of 525 companies for 3-Year EBITDA Growth Rate. This places Sophia Genetics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Sophia Genetics' value of 9.60% is 3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current 3-Year EBITDA Growth Rate of 9.60% is 3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current 3-Year EBITDA Growth Rate is 9.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.13, compared to a current price of $8.24 — trading 60.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.60% and 3% below the Healthcare Providers & Services industry median of 9.90. Sophia Genetics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current 3-Year EBITDA Growth Rate is 9.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $8.24 is trading 60.5% above its estimated GF Value™ of $5.13.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
3-Year EBITDA Growth Rate: 9.60%
GF Value™: $5.13 vs. price of $8.24 (60.5% above fair value)
Industry Position: 3% below the Healthcare Providers & Services median (#265 of 525)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
66GF Score
Get the complete analysis for SOPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
